Quick Q, Dr. T - what is your go-to resource for valid Rx and non-Rx approaches to post-Covid fatigue and cognitive difficulties? Lots of stray info out there about supplements here and there with little evidence base....Thanks for all you do.
Quick Q, Dr. T - what is your go-to resource for valid Rx and non-Rx approaches to post-Covid fatigue and cognitive difficulties? Lots of stray info out there about supplements here and there with little evidence base....Thanks for all you do.
@Dr Saxima: Perhaps you would find the research from our Biochemistry/Immunology collaborators helpful for your understanding about our concepts of the COVID19 and PASC. Gold Std EBM RCTs arenтАЩt available but in our desperation to help and not harm with some sound biological reasoning, starting in early 2020 we saw some striking outcomes in a very short time frame with no ADRs from our protocols. ItтАЩs held fast - consistent, durable and no reports of PASC. It begs for scrutiny and a blessing yet the concepts are sound and these exquisite experiments confirm what we have seen clinically so far as addressing the ultimate targets is concerned.
тАЬThe role of ╬▒7 nicotinic acetylcholine receptors in post-acute sequelae of covid-19тАЭ Maryna Skok
The latest experiment capitalizing on a therapeutic approach for COVID19 thru S-protein RBD-ACE2 binding interference is by incorporating a universal molecular chaperone, the a7nAChR that is contiguous to the ACE2. Triggering this critical molecular chaperone and potent anti-inflammatory protects this critical gateway for viral entry. The therapeutic is a positive allosteric modulator with a urea motif, specifically hydroxyUREA (HU). It is an inexpensive drug being used in a legitimate repurposed way. It has decades of use in other disorders, most on continuous use basis. Our clinical experiences, however anecdotal, support its use for early, middle and late stages of COVID19 without regard to viral variants, to date. Others have approached therapy based on the S protein-RBD-ACE2 gateway but newer variants mutated to circumvent this gateway. Dr Skok et al have demonstrated that this approach can be utilized,but only by addressing the a7NAChR chaperone contiguous with the ACE2 receptor and without interfering with the ACE2 enzymatic function. These unique discoveries need validation and the repurposed drug HU as a modulator should be placed at a priority for study in non-commercial lab research facilities for the benefit of the public at large and not stockholders investment requirements. Have a look and ask any questions:
Olena Kalashnyk, Olena Lykhmus, Raymond Sullivan, Serhiy Komisarenko, Maryna Skok
Quick Q, Dr. T - what is your go-to resource for valid Rx and non-Rx approaches to post-Covid fatigue and cognitive difficulties? Lots of stray info out there about supplements here and there with little evidence base....Thanks for all you do.
I wish there were validated treatments out there, but there aren't so much of what you'll see is unsubstantiated (and some predatory).
@Dr Saxima: Perhaps you would find the research from our Biochemistry/Immunology collaborators helpful for your understanding about our concepts of the COVID19 and PASC. Gold Std EBM RCTs arenтАЩt available but in our desperation to help and not harm with some sound biological reasoning, starting in early 2020 we saw some striking outcomes in a very short time frame with no ADRs from our protocols. ItтАЩs held fast - consistent, durable and no reports of PASC. It begs for scrutiny and a blessing yet the concepts are sound and these exquisite experiments confirm what we have seen clinically so far as addressing the ultimate targets is concerned.
тАЬThe role of ╬▒7 nicotinic acetylcholine receptors in post-acute sequelae of covid-19тАЭ Maryna Skok
https://doi.org/10.1016/j.biocel.2024.106519
Also: @Hydroxyurea interaction with ╬▒7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19тАЭ
Olena Lykhmus a, Olena Kalashnyk et al
@Greg Saxima and interested clinicians:
The latest experiment capitalizing on a therapeutic approach for COVID19 thru S-protein RBD-ACE2 binding interference is by incorporating a universal molecular chaperone, the a7nAChR that is contiguous to the ACE2. Triggering this critical molecular chaperone and potent anti-inflammatory protects this critical gateway for viral entry. The therapeutic is a positive allosteric modulator with a urea motif, specifically hydroxyUREA (HU). It is an inexpensive drug being used in a legitimate repurposed way. It has decades of use in other disorders, most on continuous use basis. Our clinical experiences, however anecdotal, support its use for early, middle and late stages of COVID19 without regard to viral variants, to date. Others have approached therapy based on the S protein-RBD-ACE2 gateway but newer variants mutated to circumvent this gateway. Dr Skok et al have demonstrated that this approach can be utilized,but only by addressing the a7NAChR chaperone contiguous with the ACE2 receptor and without interfering with the ACE2 enzymatic function. These unique discoveries need validation and the repurposed drug HU as a modulator should be placed at a priority for study in non-commercial lab research facilities for the benefit of the public at large and not stockholders investment requirements. Have a look and ask any questions:
Olena Kalashnyk, Olena Lykhmus, Raymond Sullivan, Serhiy Komisarenko, Maryna Skok
https://doi.org/10.1016/j.bbrc.2024.149825